115563
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
两性霉素 B 胶体分散液作为侵袭性真菌病挽救治疗的临床结局
Authors Jiang M, Li W, Tian L, Xu D, Fan Y, Liu D, He Y
Received 12 September 2025
Accepted for publication 31 December 2025
Published 8 January 2026 Volume 2026:20 567247
DOI https://doi.org/10.2147/DDDT.S567247
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Solomon Tadesse Zeleke
Minli Jiang,1,2,* Wei Li,1,* Lei Tian,3 Dong Xu,4 Yuanshuai Fan,5 Dong Liu,1 Yan He1
1Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China; 2Department of Pharmacy, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang, 441000, People’s Republic of China; 3Clinical Microbiology Laboratory, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China; 4Department of Infection Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China; 5Department of Pharmacy, Pu’an Hospital of Traditional Chinese Medicine, Pu’an, 561500, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yan He, Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China, Email yanhe@tjh.tjmu.edu.cn Dong Liu, Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China, Email ld2069@outlook.com
Purpose: The incidence of invasive fungal disease (IFD) has significantly increased in recent years, partly driven by the expanding immunocompromised population, as well as severe influenza and COVID-19. Amphotericin B (AmB) is highly effective against a broad spectrum of fungal infections and has a low drug resistance rate, but its clinical use is limited by toxicity. Amphotericin B colloidal dispersion (ABCD), a lipid formulation of AmB, is preferred in China for its reduced toxicity. This study assesses real-world clinical outcomes of ABCD as salvage therapy in IFD patients who failed prior treatment with triazoles or echinocandins.
Methods: We conducted a single-center, retrospective study of IFD patients who received ABCD salvage therapy between September 2021 and February 2024. Clinical data were systematically reviewed to assess the clinical outcomes of ABCD.
Results: Among the 60 patients included, the clinical response rate to ABCD was 71.7% (43/60; 95% confidence interval [CI], 59.2– 81.5%). Outcomes did not vary significantly with factors such as gender, underlying conditions, infection sites, or prior antifungal treatments. Incidence rates of hepatotoxicity, nephrotoxicity, and infusion-related reactions were 13.3%, 23.3%, and 1.7%, respectively. Five patients discontinued ABCD due to adverse events.
Conclusion: In this real-world setting, ABCD salvage therapy was associated with favorable clinical outcomes and an acceptable safety profile in IFD patients who failed prior azole or echinocandin therapy.
Keywords: amphotericin b colloidal dispersion, clinical response, invasive fungal infections, safety, salvage therapy
1Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China; 2Department of Pharmacy, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang, 441000, People’s Republic of China; 3Clinical Microbiology Laboratory, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China; 4Department of Infection Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China; 5Department of Pharmacy, Pu’an Hospital of Traditional Chinese Medicine, Pu’an, 561500, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yan He, Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China, Email yanhe@tjh.tjmu.edu.cn Dong Liu, Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China, Email ld2069@outlook.com
Purpose: The incidence of invasive fungal disease (IFD) has significantly increased in recent years, partly driven by the expanding immunocompromised population, as well as severe influenza and COVID-19. Amphotericin B (AmB) is highly effective against a broad spectrum of fungal infections and has a low drug resistance rate, but its clinical use is limited by toxicity. Amphotericin B colloidal dispersion (ABCD), a lipid formulation of AmB, is preferred in China for its reduced toxicity. This study assesses real-world clinical outcomes of ABCD as salvage therapy in IFD patients who failed prior treatment with triazoles or echinocandins.
Methods: We conducted a single-center, retrospective study of IFD patients who received ABCD salvage therapy between September 2021 and February 2024. Clinical data were systematically reviewed to assess the clinical outcomes of ABCD.
Results: Among the 60 patients included, the clinical response rate to ABCD was 71.7% (43/60; 95% confidence interval [CI], 59.2– 81.5%). Outcomes did not vary significantly with factors such as gender, underlying conditions, infection sites, or prior antifungal treatments. Incidence rates of hepatotoxicity, nephrotoxicity, and infusion-related reactions were 13.3%, 23.3%, and 1.7%, respectively. Five patients discontinued ABCD due to adverse events.
Conclusion: In this real-world setting, ABCD salvage therapy was associated with favorable clinical outcomes and an acceptable safety profile in IFD patients who failed prior azole or echinocandin therapy.
Keywords: amphotericin b colloidal dispersion, clinical response, invasive fungal infections, safety, salvage therapy